The management of uterine leiomyomas


  • George A. Vilos London, United Kingdom
  • Catherine Allaire Vancouver, Canada
  • Philippe-Yves Laberge Quebec, Canada
  • Nicholas Leyland Hamilton, Canada



myoma, leiomyoma, fibroid, myomectomy, uterine artery embolization, hysterectomy, heavy menstrual bleeding, menorrhagia


Objectives: The aim of this guideline is to provide clinicians with an understanding of the pathophysiology, prevalence, and clinical significance of myomata and the best evidence available on treatment modalities.

Options: The areas of clinical practice considered in formulating this guideline were assessment, medical treatments, conservative treatments of myolysis, selective uterine artery occlusion, and surgical alternatives including myomectomy and hysterectomy.

Outcomes: Implementation of this guideline should optimize the decision-making process of women and their health care providers in proceeding with further investigation or therapy for uterine leiomyomas, having considered the disease process and available treatment options, and reviewed the risks and anticipated benefits.

Author Biographies

George A. Vilos, London


Catherine Allaire, Vancouver


Philippe-Yves Laberge, Quebec


Nicholas Leyland, Hamilton



  1. Baird, D.D., Dunson, D.B., Hill, M.C., Cousins, D., Schectman, J.M. “High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence.” Am J Obstet Gynecol, 188(2003): 100–107.
  2. Boyd, L.R., Novesky, A.P., Curtin, J.P. “Effect of surgical volume on route of hysterectomy and short-term morbidity.” Obstet Gynecol, 116(2010): 909–915. 10. Clark-Pearson, D.L., Geller, E.L. “Complications of hysterectomy.” Obstet Gynecol, 121(2013): 654–673.
  3. Bulun, S.E. “Uterine fibroids.” N Engl J Med, 369(2013): 1344–1355.
  4. Munro, M.G., Critchley, H.O., Broder, M.S., Fraser, I.S. “The FIGO Classification System (“PA LM-COE IN”) for causes of abnormal uterine bleeding in non-gravid women in the reproductive years, including guidelines for clinical investigation.” Int J Gynaecol Obstet, 113(2011): 3–13.
  5. Flake, G.P., Andersen, J., Dixon, D. “Etiology and pathophysiology of uterine leiomyomas; a review.” Environ Health Perspect, 111(2003): 1037–1054.
  6. Lumsden, M.A., Wallace, E.M. “Clinical presentation of uterine fibroids.” Baillieres Clin Obstet Gynaecol, 12(1998): 177–195.
  7. Schwartz, L.B., Diamond, M.P., Schwartz, P.E. “Leiomyosarcomas: clinical presentation.” Am J Obstet Gynecol, 168(1 Pt 1) (1993): 180–183.
  8. Laughlin, S.K., Baird, D.D., Savitz, D.A., Herring, A.H., Hartmann, K.E. “Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound-screening study.” Obstet Gynecol, 113(2009): 630–635.
  9. Neiger, R., Sonek, J.D., Croom, C.S., Ventolini, G. “Pregnancy-related changes in the size of uterine leiomyomas.” J Reprod Med, 51(2006): 671–674.
  10. Hammoud, A.O., Asaad, R., Berman, J., Treadwell, M.C., et al. “Volume change of uterine myomas during pregnancy: do myomas really grow?” J Minim Invasive Gynecol, 13(2006): 386–390.
  11. Laughlin, S.K., Herring, A.H., Savitz, D.A., Olshan, A.F., et al. “Pregnancy-related fibroid reduction.” Fertil Steril, 94(2010): 2421–2423.
  12. De Vivo, A., Mancuso, A., Giacobbe, A., Savasta, L.M., et al. “Uterine myomas during pregnancy: a longitudinal sonographic study.” Ultrasound Obstet Gynecol, 37(2011): 361–365.
  13. Exacoustos, C., Rosati, P. “Ultrasound diagnosis of uterine myomas and complications in pregnancy.” Obstet Gynecol, 82(1993): 97–101.
  14. Sheiner, E., Bashiri, A., Levy, A., Hershkovitz, R., Katz, M., Mazor, M. “Obstetric characteristics and perinatal outcome of pregnancies with uterine leiomyomas.” J Reprod Med, 49(2004): 182–186.
  15. Qidwai, G.I., Caughey, A.B., Jacoby, A.F. “Obstetric outcomes in women with sonographically identified uterine leiomyomata.” Obstet Gynecol, 107 (2 Pt l) (2006): 376–382.
  16. Vergani, P., Locatelli, A., Ghidini, A., Andreani, M., Sala, F., Pezzullo, J.C. “Large uterine leiomyomata and risk of cesarean delivery.” Obstet Gynecol, 109 (2 Pt l) (2007): 410–414.
  17. Chen, Y.H., Lin, H.C., Chen, S.F., et al. “Increased risk of preterm births among women with uterine leiomyoma: a nationwide population-based study.” Hum Reprod, 24(2009): 3049–3056.
  18. Klatsky, P.C., Tran, N.D., Caughey, A.B., Fujimoto, V.Y. “Fibroids and reproductive outcomes: a systematic literature review from conception to delivery.” Am J Obstet Gynecol, 198(2008): 357–366.
  19. Stout, M.J., Odibo, A.O., Graseck, A.S., Macones, G.A., Crane, J.P., Cahill, A.G. “Leiomyomas at routine second-trimester ultrasound examination and adverse obstetric outcomes.” Obstet Gynecol, 116(2010): 1056–1063.
  20. Lolis, D.E., Kalantaridou, S.N., Makrydimas, G., et al. “Successful myomectomy during pregnancy.” Hum Reprod, 18(2003): 1699–1702.
  21. Mu, Y.L., Wang, S., Hao, J., Shi, M., Yelian, F.D., Wang, X.T. “Successful pregnancies with uterine leiomyomas and myomectomy at the time of caesarean section.” Postgrad Med J, 87(2011): 601–614.
  22. Gbadebo, A.A., Charles, A.A., Austin, O. “Myomectomy at caesarean section: descriptive study of clinical outcome in a tropical setting.” J Ayub Med Coll Abbottabad, 21(2009): 7–9.
  23. Park, B.J., Kim, Y.W. “Safety of cesarean myomectomy.” J Obstet Gynaecol Res, 35(2009): 906–911.
  24. Parker, W.H., Fu, Y.S., Berek, J.S. “Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.” Obstet Gynecol, 83(1994): 414–418.
  25. Leibsohn, S., d’Ablaing, G., Mishell, D.R. Jr, Schlaerth, J.B. “Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas.” Am J Obstet Gynecol, 162(1990): 968–976.
  26. Knight, J., Falcone, T. “Tissue extraction by morcellation: a clinical dilemma.” J Minim Invas Gynecol, 21(2014):319–320.
  27. Vilos, G.A., Harding, P.G., Sugimoto, A.K., Ettler, H.C., Bernier M.J. “Hysteroscopic endomyometrial resection of three uterine sarcomas.” J Am Assoc Gynecol Laparosc, 8(2001): 545–551.
  28. Ip, P.P., Tse, K.Y., Tam, K.F. “Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.” Adv Anat Pathol, 17(2010): 91–112.
  29. Vilos, G.A., Marks, J., Ettler, H.C., Vilos, A.G., et al. “Uterine smooth muscle tumors of uncertain malignant potential; diagnostic challenges and therapeutic dilemmas. Report of 2 cases and review of literature.” J Minim Invas Gynecol, 19(2012): 288–295.
  30. Cantuaria, G.H., Anglioli, R., Frost, L., Duncan, R., Penalver, M.A. “Comparison of bimanual examination with ultrasound before hysterectomy for uterine leiomyoma.” Obstet Gynecol, 92(1998): 109–112.
  31. Farquhar, C., Ekeroma, A., Furness, S., Arroll, B. “A systematic review of transvaginal ultrasonography, sonohysterography and hysteroscopy for the investigation of abnormal uterine bleeding in premenopausal women.” Acta Obstet Gynecol Scand, 82(2003): 493–504.
  32. Makris, N., Kalmantis, K., Startados, N., Papadimitriou, A., et al. “Three dimensional hysterosonography versus hysteroscopy for the detection of intracavitary uterine abnormalities.” Int J Gynecol Obstet, 95(2007): 6–9.
  33. Vercellini, P., Crosignani, P.G., Mangioni, C., Imparato, E., et al. “Treatment with a gonadotrophin releasing hormone agonist before hysterectomy for leiomyomas: results of a multicentre, randomized controlled trial.” Br J Obstet Gynaecol, 105(1998): 1148–1154.
  34. Bradley, L.D., Falcone, T., Magen, A.B. “Radiographic imaging techniques for the diagnosis of abnormal uterine bleeding.” Obstet Gynecol Clin North Am, 27(2000): 245–276.
  35. Adusumilli, S., Hussain, H.K., Caoili, E.M., Weadock, W.J., et al. “MRI of sonographically indeterminate adnexal masses.” AJR Am J Roentgenol, 187(2006): 732–740.
  36. Dueholm, M., Lundorf, E., Hansen, E.S., Ledertoug, S., Olesen, F. “Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas.” Am J Obstet Gynecol, 186(2002): 409–415.
  37. Omary, R.A., Vasireddy, S., Chrisman, H.B., Ryu, R.K., et al. “The effect of pelvic MR imaging on the diagnosis and treatment of women with presumed symptomatic uterine fibroids.” J Vase Interv Radiol, 13(2002): 1149–1153.
  38. Stamatopoulos, C.P., Mikos, T., Grimbizis, G.F., Dimitriadis, A.S., et al. “Value of magnetic resonance imaging in diagnosis of adenomyosis and myomas of the uterus.” J Minim Invas Gynecol, 19(2012): 620–626.
  39. Myers, E.R., Barber, M.D., Gustilo-Ashby, T., Couchman, G., et al. “Management of uterine leiomyomata: what do we really know?” Obstet Gynecol. 100(2002): 8–17.
  40. Peddada, S.D., Laughlin, S.K., Miner, K., Guyon, J.P., et al. “Growth of uterine leiomyomata among premenopausal black and white women.” Proc Nad Acad Sci USA, 105(2008): 19887–19892.
  41. DeWaay, D.J., Syrop, C.H., Nygaard, I.E., Davis, W.A., et al. “Natural history of uterine polyps and leiomyomata.” Obstet Gynecol, 100(2002): 3–7.
  42. Ang, W.C., Farrell, E., Vollenhoven, B. “Effect of hormone replacement therapies and selective estrogenreceptor modulators in postmenopausal women with uterine leiomyomas: a systematic review.” Climacteric, 4(2001): 284–292.
  43. Yang, C.H., Lee, J.N., Hsu, S.C., Kuo, C.H., Tsai, E.M. “Effect of hormone replacement therapy on uterine fibroids in postmenopausal women – a 3-year study.” Matuntas, 43(2002): 35–39.
  44. Al-Hendy, A., Salama, S. “Gene therapy and uterine leiomyoma: a review.” Hum Reprod Update, 12(2006): 385–400.
  45. Sayed, G.H., Zakherah, M.S., El-Nashar, S.A., Shaaban, M.M. “A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid–related menorrhagia.” Int J Gynaecol Obstet, 112(2011): 126–130.
  46. Maruo, T., Ohara, N., Yoshida, S., Nakabayashi, K., et al. “Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system.” Contraception, 82(2010): 435–441.
  47. Englund, K., Blanck, A., Gustavsson, I., et al. “Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment.” J Clin Endocrinol Metab, 11(83) (1998): 4092–4096.
  48. Magalhaes, J., Aldrighi, J.M., de Lima, G.R. “Uterine volume and menstrual patterns in users of the levonorgestrelreleasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.” Contraception, 75(2007): 193–198.
  49. Verspyck, E., Marpeau, L., Lucas, C. “Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial.” Eur J Obstet Gynecol Reprod Biol, 89(2000): 7–13.
  50. Sangkomkamhang, U.S., Lumbiganon, P., Laopaiboon, M., Mol, B.W. “Progestogens or progestogen-releasing intrauterine systems for uterine fibroids.” Cochrane Database Syst Rev, 2(2013): CD008994.
  51. Carr, B.R., Marshburn, P.B., Weatherall, P.T., et al. “An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.” J Clm Endocrinol Metab, 76(1993): 1217–1223.
  52. Friedman, A.J., Daly, M., Juneau-Norcross, M., Rein, M.S., et al. “A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen–progestin or progestin “addback” regimens for women with leiomyomata uteri.” J Clin Endocrinol Metab, 76(1993): 1439–1445.
  53. Friedman, A.J., Hoffman, D.I., Comite, F., et al. “Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group.” Obstet Gynecol, 77(1991):720–725.
  54. Reissmann, T., Diedrich K, Comaru-Schally, A.M., Schally, A.V. “Introduction of LHRH–antagonists into the treatment of gynaecological disorders.” Human Reprod, 9(1994): 767–769.
  55. Britten, J.L., Malik, M., Levy, G., Mendoza, M., Catherino, W.H. “Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.” Fertil Steril, 98(2012): 1299–1307.
  56. Panidis, D., Vavilis, D., Rousso, D., et al. “Danazol influences gonadotropin secretion acting at the hypothalamic level.” Int J Gynaecol Obstet, 45(1994): 241–246.
  57. ACO G Committee on Practice Bulletins – Gynecology. “ACO G practice bulletin: surgical alternatives to hysterectomy in the management of leiomyomas.” Int J Gynaecol Obstet, 73(2001): 285–294.
  58. Ke, L.Q., Yang, K., Li, J., Li, C.M. “Danazol for uterine fibroids.” Cochrane Database Syst Rev, 3(2009): CD007692.
  59. Sumitani, H., Shozu, M., Segawa, T., Murakami, K., Yang, H.J., Shimada, K., et al. “In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism.” Endocrinology, 141(2000): 3852–3861.
  60. Song, H., Lu, D., Navaratnam, K., Shi, G. “Aromatase inhibitors for uterine fibroids.” Cochrane Database Syst Rev, 10(2013): CD009505.
  61. Wakeling, A.E., Dukes, M., Bowler, J. “A potent specific pure antiestrogen with clinical potential.” Cancer Res, 51(1991):3867–3873.
  62. Donnez, J., Hervais Vivancos, B., Kudela, M., et al. “A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy.” Fertil Steril, 79(2003): 1380–1389.
  63. Dutertre, M., Smith, C.L. “Molecular mechanisms of selective estrogen receptor modulator (SERM) action.” J Pharmacol Exp Ther, 295(2000): 431–437.
  64. Deng, L., Wu, T., Chen, X.Y., Xie, L., Yang, J. “Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.” Cochrane Database Syst Rev, 10(2012): CD005287.
  65. Maruo, T., Ohara, N., Wang, J., Matsuo, H. “Sex steroidal regulation of uterine leiomyoma growth and apoptosis.” Hum Reprod Update, 10(2004): 207–220.
  66. Kawaguschi, K., Fujn, S., Konishi, I., Nanbu, Y., et al. “Mitotic activity in uterine leiomyomas during the menstrual cycle.” Am J Obstet Gynecol, 160(1989): 637–641.
  67. Kawaguschi, K., Fujn, S., Konishi, I., Iwai, T., et al. “Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy.” Virchows Arch A Pathol Anat Histopathol, 419(1991): 309–315.
  68. Seagaloff, A., Weed, J.C., Sternberg, W.H., Parson, W. “The progesterone therapy of human uterine leiomyomas.” J Clin Endocrinol Metab, 9(1949): 1273–1291.
  69. Friedman, A.J., Daly, M., Juneau-Norcross, M., Gleason, R., et al. “Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen– progestin or progestin c add-back’ for 2 years.” Hum Reprod, 9(1994): 1618–1625.
  70. Chwalisz, K., Perez, M.C., Demanno, D., Winkel, C., et al. “Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.” Endocr Rev, 26(2005): 423–438.
  71. Shen, Q., Hua, Y., Jiang, W., Zhang, W., et al. “Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis.” Fertil Steril, 100(2013): 1722–1726.
  72. Chabbert-Buffet, N., Pintiaux-Kairis, A., Bouchard, P.; VA2914 Study Group. “Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebocontrolled trial.” J Clin Endocrinol Metab, 92(2007): 3582–3589.
  73. Donnez, J., Tatarchuk, T.F., Bouchard, P., Puscasiu, L., Zakharenko, N.F., Ivanova, T., et al. “Ulipristal acetate versus placebo for fibroid treatment before surgery.” N Engl J Med, 366(2012): 409–420.
  74. Donnez, J., Tomaszewski, J., Vazquez, F., Bouchard, P., Lemieszczuk, B., Baro, F., et al. “Ulipristal acetate versus leuprolide acetate for uterine fibroids.” N Engl J Med, 366(2012): 421–432.
  75. Donnez, J., Vazquez, F., Tomaszewski, J., Noun, K., et al. “PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate.” Fertil Steril, 101(6) (2014): 1565–1573.
  76. Weber, A.M., Mitchinson, A.R., Gidwani, G.P., Mascha, E., Walters, M.D. “Uterine myomas and factors associated with hysterectomy in premenopausal women.” Am J Obstet Gynecol, 176(1997): 1213–1217.
  77. Friedman, A.J., Haas, S.T. “Should uterine size be an indication for surgical intervention in women with myomas?” Am J Obstet Gynecol, 168 (3 Pt 10) (1993): 751–755.
  78. Lefebvre, G., Allaire, A., Jeffrey, J., Vilos, G. “Hysterectomy; Society of Obstetricians Clinical Practice Committee. SOGC Clinical Practice Guidelines, No. 109, January 2002.” J Obstet Gynaecol Can, 24(2002): 37–48.
  79. Thakar, R., Ayers, S., Clarkson, P., Stanton, S., Manyonda, I. “Outcomes after total versus subtotal abdominal hysterectomy.” N Engl J Med, 347(2002): 1318–1325.
  80. Learman, L.A., Summitt, R.L. Jr, Varner, R.E., McNeeley, S.G., et al. “Total or Supracervical Hysterectomy (TO SH) Research Group. A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes.” Obstet Gynecol, 102(2003): 453–462.
  81. American Association of Gynecologic Laparoscopists (AAGL). “Practice report: practice guidelines for laparoscopic/subtotal supracervical hysterectomy.” J Minim Invas Gynecol, 21(2014): 9–16.
  82. Garcia, C.R. “Management of the symptomatic fibroid in women older than 40 years of age: hysterectomy or myomectomy?” Obstet Gynecol Clin North Am, 20(1993):337-338.
  83. Cagnacci, A., Pirillo, D., Malmusi, S., Arangino, S., Alessandrini, C., Volpe, A. “Early outcome of myomectomy by laparotomy, minilaparotomy and laparoscopically assisted minilaparotomy. A randomized prospective study.” Hum Reprod, 18(2003): 2590–2594.
  84. American Association of Gynecologic Laparoscopists (AAGL): Advancing Minimally Invasive Gynecology Worldwide. “AAGL practice report: practice guidelines for the diagnosis and management of submucous leiomyomas.” J Minim Invasive Gynecol, 19(2012): 152–171.
  85. Munro, M.G. “Abnormal uterine bleeding: surgical management – part 3.” J Am Assoc Gynecol Laparosc, 8(2001): 18–47.
  86. College National des Gynecologues et Obstetnciens Frangais (CNGOF). “Actualisation de la prise en charge des myomes (Myoma management recommandations).” J Gynecol Obstet Biol Reprod, 40(2011): 693–708.
  87. Wamsteker, K., Emanuel, M.H., de Kruif, J.H. “Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension.” Obstet Gynecol, 82(1993): 736–740.
  88. Emanuel, M.H., Wamsteker, K., Hart, A.A., Metz, G., Lammes, F.B. “Long-term results of hysteroscopic myomectomy for abnormal uterine bleeding.” Obstet Gynecol, 93 (5 Pt l) (1999): 743–748.
  89. Hart, R., Molnar, B.G., Magos, A. “Long-term follow-up of hysteroscopic myomectomy assessed by survical analysis.” Br J Obstet Gynaecol, 106(1999): 700–705.
  90. Marziani, R., Mossa, B., Ebano, V., Periola, G., et al. “Transcervical myomectomy: long-term effects on abnormal uterine bleeding.” Clin Exp Obstet Gynecol, 32(2005): 23–26.
  91. Bradley, L.D. “Complications in hysteroscopy: prevention, treatment and legal risk.” Curr Opin Obstet Gynecol, 14(2002): 409–415.
  92. Vilos, G.A. Chapter on hysteroscopic surgery: indications, contraindications and complications. In: Pasic, R., Levine, R.A. Practical manual of hysteroscopy and endometrial ablation: a clinical cookbook. Boca Raton, FL: CRC Press (2004): 237–258.
  93. Jin, C., Hu, Y., Chen, X.C., Zheng, F.Y., Lin, F., Zhou, K., et al. “Laparoscopic versus open myomectomy – a meta-analysis of randomized controlled trials.” Eur J Obstet Gynecol Reprod Biol, 145(2009): 14–21.
  94. Holzer, A., Jirecek, S.T., Illievich, U.M., Huber, J., Wenzl, R.J. “Laparoscopic versus open myomectomy: a double-blind study to evaluate postoperative pain.” Anesth Analg, 102(2006): 1480–1484.
  95. Alessandri, F., Lijoi, D., Mistrangelo, E., Ferrero, S., Ragni, N. “Randomized study of laparoscopic versus minilaparotomic myomectomy for uterine myomas.” J Minim Invasive Gynecol, 13(2006): 92–97.
  96. Malzoni, M., Tirelli, R., Cosentino, F., Luzzolino, D., et al. “Laparoscopy versus minilaparotomy in women with symptomatic uterine myomas: short-term and fertility results.” Fertil Steril, 93(2010): 2368–2373.
  97. Sinha, R., Hegde, A., Warty, N., Patil, N. “Laparoscopic excision of very large myomas.” J Am Assoc Gynecol Laparosc, 10(2003): 461–468.
  98. Lemyre, M., Bujold, E., Lathi, R., Bhagan, L., et al. “Comparison of morbidity associated with laparoscopic myomectomy and hysterectomy for the treatment of uterine leiomyomas.” J Obstet Gynaecol Can, 34(2012): 57–62.
  99. Gyamfi-Bannerman, C., Gilbert, S., Landon, M.B., et al. “Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Risk of uterine rupture and placenta accreta with prior uterine surgery outside of the lower segment.” Obstet Gynecol, 120(2012): 1332–1337.
  100. Kumakiri, J., Takeuchi, H., Itoh, S., Kitade, M., et al. “Prospective evaluation for the feasibility and safety of vaginal birth after laparoscopic myomectomy.” J Minim Invasive Gynecol, 15(2008): 420–424.
  101. Seracchioli, R., Manuzzi, L., Vianello, F., Gualerzi, B., et al. “Obstetric and delivery outcome of pregnancies achieved after laparoscopic myomectomy.” Fertil Steril, 86(2006): 159–165.
  102. Dicle, O., Kucukler, C., Pirnar, T., Erata, Y., Posaci, C. “Magnetic resonance imaging evaluation of incision healing after cesarean sections.” Eur Radiol, 7(1997): 31–34.
  103. Seracchioli, R., Rossi, S., Govoni, F., Rossi, E., et al. “Fertility and obstetric outcome after laparoscopic myomectomy of large myomata: a randomized comparison with abdominal myomectomy.” Hum Reprod, 15(2000): 2663–2668.
  104. Hurst, B.S., Matthew, M.L., Marshburn, P.B. “Laparoscopic myomectomy for symptomatic uterine myomas.” Fertil Steril, 83(2005): 1–23.
  105. Prapas, Y., Kalogiannidis, I., Prapas, N. “Laparoscopy vs laparoscopically assisted myomectomy in the management of uterine myomas: a prospective study.” Am J Obstet Gynecol, 200(2009): 144–146.
  106. Wright, J.D., Ananth, C.V., Lewin, S.N., Burke, W.M., et al. “Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease.” JAMA , 309(2013): 689–698.
  107. Gargiulo, A.R., Srouji, S.S., Missmer, S.A., Correia, K.F., et al. “Robot-assisted laparoscopic myomectomy compared with standard laparoscopic myomectomy.” Obstet Gynecol, 120 (2 Pt 1) (2012): 284–291.
  108. Liu, H., Lu, D., Wang, L., Shi, G., Song, H., Clarke, J. “Robotic surgery for benign gynaecological disease.” Cochrane Database Syst Rev, 2(2012): CD008978.
  109. AAGL Advancing Minimally Invasive Gynecology Worldwide. “AAGL position statement: robotic-assisted laparoscopic surgery in benign gynecology.” J Minim Invasiv Gynecol, 20(2013): 2–9.
  110. Milad, M., Milad, E. “Laparoscopic morcellator-related complications.” J Minim Invas Gynecol, 21(2014): 486–491.
  111. Sizzi, O., Rossetti, A., Malzoni, M., Minelli, L., et al. “Italian multicenter study on complications of laparoscopic myomectomy.” J Minim Invasive Gynecol, 14(2007): 453–462.
  112. Cucinella, G., Granese, R., Calagna, G., Somigliana, E., Perino, A. “Parasitic myomas after laparoscopic surgery: an emerging complication in the use of morcellator? Description of four cases.” Fertil Steril, 96(2011): 90–96.
  113. Hilger, W.S., Magrina, J.F. “Removal of pelvic leiomyomata and endometriosis five years after supracervical hysterectomy.” Obstet Gynecol, 108 (3 Pt 2) (2006): 772–774.
  114. Hutchins, F.L. Jr, Reinoehl, E.M. “Retained myoma after laparoscopic supracervical hysterectomy with morcellation.” J Am Assoc Gynecol Laparosc, 5(1998): 293–295.
  115. Ordulu, Z., Dal Cin, P., Chong, W.W.S., Choy, K.W., et al. “Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.” Genes Chromosomes Cancer, 49(2010): 1152–1160.
  116. Sinha, R., Sundaram, M., Mahajan, C., Sambhus, A. “Multiple leiomyomas after laparoscopic hysterectomy: report of two cases.” J Minim Invasive Gynecol, 14(2007): 123–127.
  117. Worthington-Kirsch, R., Hutchins, F.J. Jr. “Retained myoma fragment after LASH procedure.” Clin Radiol, 56(2001): 777–778.
  118. Sinha, R., Sundaram, M., Lakhotia, S. “Recurrent leiomyomatosis.” J Minim Invas Gynecol, 16(2009): 668.
  119. Ribic-Pucelj, M., Cvjeticanin, B., Salamun, V. “Leiomyomatosis peritonealis disseminata as a possible result of laparoscopic myomectomy – report of four cases.” Gynecol Surg, 10(2013): 253–256.
  120. Health Canada. Laparoscopic electric morcellators – risk of spread of unsuspected uterine sarcoma – notice to hospitals. Ottawa. Health Canada (2014).
  121. Mussalam, K.M., Tamim, H.M., Richards, T., et al. “Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study.” Lancet, 378(980) (2011): 1396–1407.
  122. Lethaby, A., Vollenhoven, B., Sowter, M. “Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.” Cochrane Database Syst Rev, (2)2001: CD000547.
  123. Chen, I., Motan, T., Kiddoo, D. “Gonadotropin-releasing hormone agonist in laparoscopic myomectomy: systematic review and meta-analysis of randomized controlled trials.” J Minim Invasive Gynecol, 18(2011): 303–309.
  124. De Falco, M., Staibano, S., Mascolo, M., et al. “Leiomyoma pseudocapsuleafter pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes.” Eur J Obstet Gynecol Reprod Biol, 144(2009): 44–47.
  125. Mavrelos, D., Ben–Nagi, J., Davies, A., Lee, C., et al. “The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial.” Hum Reprod, 25(2010): 2264–2269.
  126. Chang, F.W., Yu, M.H., Ku, C.H., Chen, C.H., Wu, G.J., Liu, J.Y. “Effect of uterotonics on intra-operative blood loss during laparoscopy – assisted vaginal hysterectomy: a randomised controlled trial.” BJOG, 113(2006): 47–52.
  127. Celik, H., Sapmaz, E. “Use of a single preoperative dose of misoprostol is efficacious for patients who undergo abdominal myomectomy.” Fertil Steril, 79(2003): 1207–1210.
  128. Frederick, S., Frederick, J., Fletcher, H., Reid, M., et al. “A trial comparing the use of rectal misoprostol plus perivascular vasopressin with perivascular vasopressin alone to decrease myometrial bleeding at the time of abdominal myomectomy.” Fertil Steril, 100(2013): 1044–1049.
  129. Cesen-Cummings, K., Houston, K.D., Copland, J.A., et al. “Uterine leiomyomas express myometrial contractile-associated proteins involved in pregnancy-related hormone signaling.” J Soc Gynecol Investig, 10(2003): 11–20.
  130. Wang, C.J., Yuen, L.T., Yen, C.F., Lee, C.L., Soong, Y.K. “A simplified method to decrease operative bloodloss in laparoscopicassisted vaginal hysterectomy for the large uterus.” J Am Assoc Gynecol Laparosc, 11(2004): 370–373.
  131. Kongnyuy, E.J., Wiysonge, C.S. “Interventions to reduce haemorrhage during myomectomy for fibroids.” Cochrane Database Syst Rev, 11(2011): CD005355.
  132. Riess, M.L., Ulrichs, J.G., Pagel, P.S., Woehlck, H.J. “Case report: severe vasospasm mimics hypotension after high-dose intrauterine vasopressin.” Anesth Analg, 113(2011): 1103–1105.
  133. Ginsburg, E.S., Benson, C.B., Garfield, J.M., et al. “The effect of operative technique and uterine size on blood loss during myomectomy: a prospective randomized study.” Fertil Steril, 60(1993): 956–962.
  134. Fletcher, H., Frederick, J., Hardie, M., Simeon, D. “A randomized comparison of vasopressin and tourniquet as hemostatic agents during myomectomy.” Obstet Gynecol, 87(1996): 1014–1018.
  135. Zhao, F., Jiao, Y., Guo, Z., Hou, R., Wang, M. “Evaluation of loop ligation of larger myoma pseudocapsule combined with vasopressin on laparoscopic myomectomy.” Fertil Steril, 95(2011): 762–766.
  136. Zullo, F., Palomba, S., Corea, D., Pellicano, M., et al. “Bupivacaine plus epinephrine for laparoscopic myomectomy: a randomized placebo-controlled trial.” Obstet Gynecol, 104(2004): 243–249.
  137. Wellington, K., Wagstaff, A.J. “Tranexamic acid: a review of its use in the management of menorrhagia.” Drugs, 63(2003): 1417–1433.
  138. Caglar, G.S., Tasci, Y., Kayikcioglu, F., Haberal, A. “Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study.” Eur J Obstet Gynecol Reprod Biol, 137(2008): 227–231.
  139. Bae, J.H., Chong, G.O., Seong, W.J., Hong, D.G., Lee, Y.S. “Benefit of uterine artery ligation in laparoscopic myomectomy.” Fertil Steril, 95(2011): 775–778.
  140. Chang, W.C., Huang, P.S., Wang, P.H., Chang, D.Y., et al. “Comparison of laparoscopic myomectomy using in situ morcellation with and without uterine artery ligation for treatment of symptomatic myomas.” J Minim Invasive Gynecol, 19(2012): 715–721.
  141. Ikechebelu, J.I., Ezeama, C.O., Obiechina, N.J. “The use of tourniquet to reduce blood loss at myomectomy.” Niger J Clin Pract, 13(2010): 154–158.
  142. Taylor, A., Sharma, M., Tsirkas, P., Di Spiezio Sardo, A., et al. “Reducing blood loss at open myomectomy using triple tourniquets: a randomised controlled trial.” BJOG, 112(2005): 340–345.
  143. Tinelli, A., Malvasi, A., Guido, M., Tsin, D.A., Hudelist, G., Hurst, B., et al. “Adhesion formation after intracapsular myomectomy with or without adhesion barrier.” Fertil Steril, 95(2011): 1780–1785.
  144. Mettler, L., Hucke, J., Bojahr, B., Tinneberg, H.R., et al. “A safety and efficacy study of a resorbable hydrogel for reduction of post-operative adhesions following myomectomy.” Hum Reprod, 23(2008): 1093–1100.
  145. Takeuchi, H., Kitade, M., Kikuchi, I., et al. “Adhesion-prevention effects of fibrin sealants after laparoscopic myomectomy as determined by second-look laparoscopy: a prospective, randomized, controlled study.” J Reprod Med, 50(2005): 571–577.
  146. Pron, G., Mocarski, E., Bennett, J., Vilos, G., et al. “Ontario UFE Collaborative Group. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial.” Obstet Gynecol, 105(2005): 67–76.
  147. Mara, M., Kubinova, K. “Embolization of uterine fibroids from the point of view of the gynecologist: pros and cons.” Int J Womens Health, 6(2014): 623–629.
  148. Martin, J., Bhanot, K., Athreya, S. “Complications and reinterventions in uterine artery embolization for symptomatic uterine fibroids: a literature review and meta-analysis.” Cardiovasc Intervent Radiol, 36(2013): 395–402.
  149. Zupi, E., Sbracia, M., Marconi, D., Munro, M.G. “Myolysis of uterine fibroids: is there a role?” Clin Obstet Gynecol, 49(2006): 821–833.
  150. National Institute for Health and Clinical Excellence (NICE). IPG 413: magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids. London. NICE (2014).
  151. Ghezzi, F., Cromi, A., Bergamini, V., Scarperi, S., et al. “Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas.” Surg Endosc, 21(2007): 2081–2085.
  152. Pansky, M., Cowan, B.D., Frank, M., Hampton, H.L., Zimberg, S. “Laparoscopically assisted uterine fibroid cryoablation.” Am J Obstet Gynecol, 201(2009): 571–577.
  153. Bourlev, V., Pavlovitch, S., Stygar, D., Volkov, N., et al. “Different proliferative and apoptotic activity in peripheral versus central parts of human uterine leiomyomas.” Gynecol Obstet Invest, 55(2003): 199–204.
  154. Munro, M.G.; Southern California Permanente Medical Group’s Abnormal Uterine Bleeding Working Group. “Acute uterine bleeding unrelated to pregnancy: a Southern California Permanente Medical Group practice guideline.” Perm J, 17(2013): 43–56.
  155. Friedman, A.J. “Combined oestrogen-progestin treatment of vaginal hemorrhage following gonadotropin-releasing hormone agonist therapy of uterine myomas.” Hum Reprod, 8(1993): 540–542.
  156. Thomas, M.A., Gass, M.L., Scott, M.C., Liu, J.H. “Multiple therapies for vaginal bleeding secondary to large uterine myomas.” Int J Gynaecol Obstet, 36(1991): 239–241.
  157. Lakhari, K.P., Marsh, M.S., Purcell, W., Hardiman, P. “Uterine artery blood flow parameters in women with dysfunctional uterine bleeding and uterine fibroids: the effects of tranexamic acid.” Ultrasound Obstet Gynecol, 11(1998): 23–28.
  158. Lukes, A.S., Moore, I.A., Muse, K.N., Gersten, J.K., et al. “Tranexamic acid treatment for heavy menstrual bleeding a randomized controlled trial.” Obstet Gynecol, 116(2010): 865–875.
  159. Naoulou, B., Tsai, M.C. “Efficacy of tranexamic acid in the treatment of idiopathic and nonfunctional heavy menstrual bleeding: a systematic review.” Acta Obstet Gynecol Scand, 91(2012): 529–537.
  160. Lindoff, C., Rybo, G., Astedt, B. “Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.” Thromb Haemost, 70(1993): 238–240.
  161. Sundstrom, A., Seaman, H., Kieler, H., Alfredsson, L. “The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a casecontrol study using the General Practice Research Database.” BJOG, 116(2009): 91–97.
  162. Donnez, J., Tomaszewski, J., Vazquez, F., Bouchard, P., et al. “Ulipristal acetate versus leuprolide acetate for uterine fibroids.” N Engl J Med, 366(2012): 421–432.
  163. Hamani, Y., Ben-Shachar, I., Kalish, Y., Porat, S. “Intrauterine balloon tamponade as a treatment for immune thrombocytopenic purpura- induced severe uterine bleeding.” Fertil Steril, 94 (2010): 2769.e13–2769.e15.
  164. Goldrath, M.H. “Uterine tamponade for the control of acute uterine bleeding.” Am J Obstet Gynecol, 147(1983): 869–872.
  165. Thorp, J.M., Katz, V.L. “Submucous myomas treated with gonadotropin-releasing hormone agonist and resulting in vaginal hemorrhage. A case report.” J Reprod Med, 36(1991): 625–626.
  166. Richards, S.R. “Endometrial ablation for life-threatening abnormal uterine bleeding. A report of two cases.” J Reprod Med, 39(1994): 741–742.
  167. Osuga, Y., Okagaki, R., Ozaki, S., Matsumi, H., et al. “Successful emergency endometrial ablation for intractable uterine bleeding in a postmenopausal woman complicated with liver cirrhosis and morbid obesity.” Surg Endosc, 15(2001): 898.



How to Cite

Vilos, G. A., Allaire, C., Laberge, P.-Y., & Leyland, N. (2015). The management of uterine leiomyomas. REPRODUCTIVE ENDOCRINOLOGY, (24), 59–73.



Tumors and pretumoral pathology